. Author manuscript; available in PMC: 2020 Apr 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2019 Jul 23;28(10):1612–1620. doi: 10.1158/1055-9965.EPI-19-0466

Table 5:

Adjusted ORs (aORs) associated with development of SMN based on multivariable analysis: all matched sets with data on BMI at end of therapy (EOT), n=50

	Multivariable Model 3			Multivariable Model 4
	aOR	95% CI	p value	aOR	95%CI	p value

BMI Category at EOT
Normal/Underweight	1.00	Ref	-
Overweight	0.46	0.12–1.74	0.25
Obese	2.65	0.99–7.09	0.051
Global Null Hypothesis Test	-	-	*0.03*

BMI Category Change Diagnosis to EOT
Not Obese to Not Obese				1.00	Ref	-
Not Obese to Obese				2.23	0.63–7.89	0.21
Obese to Not Obese				1.05	0.15–7.53	0.96
Obese to Obese				4.44	1.37–14.34	0.013
Global Null Hypothesis Test				-	-	0.079

Cumulative Epipodophyllotoxin Dose
0	1.00	Ref	-	1.00	Ref	-
1–1800 mg/m²	2.90	0.92–9.14	0.07	3.03	0.96–9.61	0.059
1801+ mg/m²	1.89	0.59–6.04	0.28	2.10	0.65–6.77	0.21
Global Null Hypothesis Test	-	-	0.19	-	-	0.15

Factors with p <0.10 in univariate analysis included in multivariable model. SMN=second malignant neoplasm; EOT=end of therapy.